Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 139Terminated 49Unknown 27Recruiting 18Active not recruiting 14Withdrawn 8Not yet recruiting 4Suspended 3

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Vascular Malformations 1Nevus 1Lymphangioma 1Hemangioma 1Hemangioendothelioma 1Colonic Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1Arteriovenous Malformations 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Everolimus × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT06561022 2024-08-19

abemaSNF1/3

Fudan University

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms

NCT06301386 2024-03-08

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Fudan University

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡